(Q39270687)

10 September 2017

title

Antischizophrenic drugs: Differential plasma protein binding and therapeutic activity (English)

1 reference

https://api.crossref.org/works/10.1016/0024-3205(79)90457-0

2 November 2022

1

Freedberg KA

1 reference

10 September 2017

R. B. Innis

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A39211

2 November 2022

I. Creese

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A39211

2 November 2022

S. H. Snyder

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A39211

2 November 2022

language of work or name

English

0 references

publication date

1 June 1979

1 reference

10 September 2017

25 June 1979

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=39211

full work available at URL

2 November 2022

https://api.elsevier.com/content/article/PII:0024320579904570?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/0024-3205(79)90457-0

https://api.elsevier.com/content/article/PII:0024320579904570?httpAccept=text/plain

2 November 2022

1 reference

https://api.crossref.org/works/10.1016/0024-3205(79)90457-0

2 November 2022

1 reference

10 September 2017

volume

24

1 reference

10 September 2017

issue

26

1 reference

10 September 2017

page(s)

2467-2473

1 reference

Clinical response and plasma levels: effect of dose, dosage schedules, and drug interactions on plasma chlorpromazine levels

10 September 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1016/0024-3205(79)90457-0

Neuroleptic drug levels and therapeutic response: preliminary observations with red blood cell bound butaperazine

2 November 2022

2

1 reference

https://api.crossref.org/works/10.1016/0024-3205(79)90457-0

Clinical significance of plasma chlorpromazine levels. I. Plasma levels of the drug, some of its metabolites and prolactin during acute treatment

2 November 2022

5

1 reference

https://api.crossref.org/works/10.1016/0024-3205(79)90457-0

Physiologic and clinical effects of chlorpromazine and their relationship to plasma level

2 November 2022

6

1 reference

https://api.crossref.org/works/10.1016/0024-3205(79)90457-0

Plasma protein binding of chlorpromazine

2 November 2022

7

1 reference

https://api.crossref.org/works/10.1016/0024-3205(79)90457-0

Plasma binding and the affinity of propranolol for a beta receptor in man

2 November 2022

8

1 reference

https://api.crossref.org/works/10.1016/0024-3205(79)90457-0

Determination of nanogram quantities of chlorpromazine and some of its metabolites in plasma using gas-liquid chromatography with an electron capture detector

2 November 2022

9

1 reference

https://api.crossref.org/works/10.1016/0024-3205(79)90457-0

Plasma levels of chlorpromazine and some of its relatively non-polar metabolites in psychiatric patients

2 November 2022

10

1 reference

https://api.crossref.org/works/10.1016/0024-3205(79)90457-0

Effects of chlorpromazine and three metabolites on behavioral responses in rats

2 November 2022

11

1 reference

https://api.crossref.org/works/10.1016/0024-3205(79)90457-0

A comparative pharmacological study of a series of monohydroxylated and methoxylated chlorpromazine derivatives

2 November 2022

12

1 reference

https://api.crossref.org/works/10.1016/0024-3205(79)90457-0

Effect of chlorpromazine and some of its metabolites on synthesis and turnover of catecholamines formed from 14C-tyrosine in mouse brain

2 November 2022

13

1 reference

https://api.crossref.org/works/10.1016/0024-3205(79)90457-0

Effect of metabolites of chlorpromazine on plasma prolactin levels in male rats

2 November 2022

14

1 reference

https://api.crossref.org/works/10.1016/0024-3205(79)90457-0

A comparison of the effects of chlorpromazine, 7-hydroxychlorpromazine and chlorpromazine sulfoxide on the activity of central dopaminergic neurons

2 November 2022

15

1 reference

https://api.crossref.org/works/10.1016/0024-3205(79)90457-0

3H-haloperidol binding to dopamine receptors in rat corpus striatum: Influence of chlorpromazine metabolites and derivatives

2 November 2022

16

1 reference

https://api.crossref.org/works/10.1016/0024-3205(79)90457-0

Dopamine Receptors in the Brain

2 November 2022

17

1 reference

https://api.crossref.org/works/10.1016/0024-3205(79)90457-0

The relationship of plasma chlorpromazine to its 7-hydroxy and sulphoxide metabolites in a large population of chronic schizophrenics

2 November 2022

19

1 reference

https://api.crossref.org/works/10.1016/0024-3205(79)90457-0

Correlation between plasma chlorpromazine and its metabolites and clinical ratings in patients with acute relapse of schizophrenic and paranoid psychosis

2 November 2022

20

1 reference

https://api.crossref.org/works/10.1016/0024-3205(79)90457-0

The possible role of metabolites in therapeutic response to chlorpromazine treatment

2 November 2022

22

1 reference

https://api.crossref.org/works/10.1016/0024-3205(79)90457-0

A simple and sensitive radioreceptor assay for antischizophrenic drugs in blood

2 November 2022

23

1 reference

https://api.crossref.org/works/10.1016/0024-3205(79)90457-0

Plasma levels and half lives of thioridazine and some of its metabolites. I. High doses in young acute schizophrenics

2 November 2022

24

1 reference

https://api.crossref.org/works/10.1016/0024-3205(79)90457-0

Serum levels of thioridazine in psychiatric patients and healthy volunteers

2 November 2022

25

1 reference

https://api.crossref.org/works/10.1016/0024-3205(79)90457-0

Binding of thioridazine and thioridazine metabolites to serum proteins in psychiatric patients

2 November 2022

31

1 reference

https://api.crossref.org/works/10.1016/0024-3205(79)90457-0

A mass fragmentographic method for the determination of chlorpromazine and two of its active metabolites in human plasma and CSF.

2 November 2022

33

1 reference

https://api.crossref.org/works/10.1016/0024-3205(79)90457-0

Dopamine Receptor Binding Predicts Clinical and Pharmacological Potencies of Antischizophrenic Drugs

2 November 2022

34

1 reference

https://api.crossref.org/works/10.1016/0024-3205(79)90457-0

2 November 2022

Identifiers

1 reference

10 September 2017

1 reference